Datar Cancer Genetics Launches Exacta AI to Offer Personalized Treatment Options for Cancer Patients

Shots: Datar Cancer Genetics has introduced Exacta AI (multi-analyte platform) to provide ~10 evidence-based drug combinations as a treatment for cancer patients who have exhausted SoC options Exacta AI integrates 360° tumor work-up with AI-driven analysis of complex tumor interactome data to assess drug interactions, toxicity, & side effects for ADCs, CPIs, targeted therapies,…

ByRidhi RastogiFebruary 4, 2025

News

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Shots: Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development…

BySenior EditorJanuary 10, 2025

THOUGHTSPOT

The Role of CCL17 in Immune Regulation: Unlocking New Therapeutic Possibilities

The CCL17 gene, a key player in the human immune system, has garnered significant attention for its role in disease regulation. This chemokine gene is pivotal in mediating immune responses, acting as a messenger that guides immune cells to sites of inflammation. Understanding its function and regulation is essential for unraveling the complexities of immune-related…

ByYan LiaoNovember 8, 2024

VIEWPOINTS

Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots

Shots: East Asia and East Europe report significant incidences of Gastric Cancer. In 2022, Japan registered around 44,000 mortalities due to Gastric Cancer VYLOY, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, received Japan’s approval in combination with chemotherapy for patients with HER2 -ve, CLDN18.2+ve, unresectable, advanced, or recurrent gastric cancer Today, at PharmaShots we have Moitreyee…

BySaurabh ChaubeyJune 24, 2024

VIEWPOINTS

Onchilles Pharma at AACR 2024: Lev Becker in a Stimulating Conversation with PharmaShots

Shots: Recently, Onchilles Pharma unveiled findings from the late-stage preclinical data of its two candidates: N17350 and N17465 Today at PharmaShots, we had an engaging dialogue exchange with Lev Becker, Associate Professor, University of Chicago and Cofounder, Onchilles Pharma Lev highlights the unique novel mechanism that Onchilles Pharma leverages to treat a wide range of…

BySaurabh ChaubeyJune 19, 2024

THOUGHTSPOT

Here’s How Environmental Health Shapes Public Welfare

Environmental health is a crucial aspect of public welfare that encompasses the interactions between people and their environment. It focuses on the physical, chemical, and biological factors that impact human health and seeks to prevent and control environmental hazards that can lead to disease or injury. The importance of environmental health cannot be overstated as…

ByCarla AdamsJune 11, 2024

INSIGHTS+

Know Your Investor (February Edition): F-Prime Capital Partners

Shots: Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare and technology A total of 40 investments were closed by F-Prime in 2023,…

BySenior EditorFebruary 27, 2024

SPOTLIGHT

Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots

PharmaShots’ Spotlight offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people. This week at the Spotlight, we had a riveting discussion with David A. Dodd, Chairman, President & CEO, at GeoVax Labs. David eloquently highlighted GeoVax’s extraordinary journey over the years from…

ByHimanshu SehgalFebruary 26, 2024

VIEWPOINTS

In an Insightful Conversation with PharmaShots, Betty Woo Highlights Thermo Fisher’s Cell Therapy Collaboration Program

Shots: Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program Betty believes that through innovation and partnership, they can tap into the full…

BySaurabh ChaubeyNovember 30, 2023

VIEWPOINTS

Moitreyee Chatterjee-Kishore, in an absorbing conversation with PharmaShots, shares the highlights of the SPOTLIGHT & GLOW study

Shots: Moitreyee Chatterjee-Kishore, HOD, Immuno-Oncology & Cancer Cell Therapy at Astellas shares insights from the P-III trials (SPOTLIGHT & GLOW) In SPOTLIGHT and GLOW, zolbetuximab and chemotherapy demonstrated improved PFS and OS vs placebo plus chemotherapy, yielding positive outcomes for patients with advanced gastric or GEJ cancer. Moitreyee highlights the ongoing clinical trials for the…

BySaurabh ChaubeyNovember 29, 2023

Datar Cancer Genetics Launches Exacta AI to Offer Personalized Treatment Options for Cancer Patients

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

The Role of CCL17 in Immune Regulation: Unlocking New Therapeutic Possibilities

Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots

Onchilles Pharma at AACR 2024: Lev Becker in a Stimulating Conversation with PharmaShots

Here’s How Environmental Health Shapes Public Welfare

Know Your Investor (February Edition): F-Prime Capital Partners

Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots

In an Insightful Conversation with PharmaShots, Betty Woo Highlights Thermo Fisher’s Cell Therapy Collaboration Program

Moitreyee Chatterjee-Kishore, in an absorbing conversation with PharmaShots, shares the highlights of the SPOTLIGHT & GLOW study

Contact US

FOLLW US

FOLLW US

Sign Up to Our Newsletter